The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% of their body weight in a mid-stage ...

U.S. equities were mixed at midday following comments from President-elect Trump about new tariffs on Chinese, Canadian, and ...

Shares of General Motors and Ford fall after President-elect Donald Trump announces his tariff plans, while Amgen tumbles as ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

The 30-stock Dow popped roughly 440 points, or about 1%, to a new record close during regular trading. The S&P 500 gained 0.3 ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Two Street analysts weigh in on Amgen's phase 2 MariTide data, saying that they would like to see additional details on the ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.